Response’s post-GLP-1RA drug reduces weight rebound in Phase II
Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like peptide-1 receptor agonists…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Spectral Medical eyes US approval of endotoxic septic shock device
Spectral Medical and partner Vantive are ploughing ahead with an application for the approval of their endotoxic septic shock therapy…
-
Perioperative Padcev and Keytruda improves survival in MIBC
Pfizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended survival in certain patients with muscle-invasive bladder…
-
Novartis’ mAb could become first Sjögren’s disease drug after Phase III success
Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III…
-
Assembly Bio’s herpes drug shows 94% drop in viral shedding
Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase…
-
Epkinly breaks ground in Phase III FL trial
Genmab and AbbVie’s subcutaneous bispecific antibody Epkinly (epcoritamab) has met its dual primary endpoints as a second-line combination therapy in…
-
Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight loss
Eli Lilly’s oral glucagon-like peptide receptor agonist (GLP-1RA) has met the primary and secondary endpoints in a Phase III trial,…
-
Novo Nordisk to advance ATTR amyloidosis mAb to Phase III
Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials. The Danish pharma…
-
HMNC focuses on MDD subgroup following efficacy signal in Phase IIb trial
HMNC Brain Health is advancing its multiple depressive disorder (MDD) drug to Phase III trials following promising Phase IIb results,…
-
Praxis’ vormatrigine eliminates seizures in 22% of patients in Phase II trial
Praxis Precision Medicines’ oral vormatrigine stopped 100% of seizures in 22% of patients in a Phase II trial. The RADIANT…
